[Malignant blood diseases and fungal infection: what does mycology provide in the year 2001?].
del Palacio
A
A
Cuétara
M S
MS
Ortiz
M C
MC
D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects; D001228:Aspergillosis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D015415:Biomarkers / Q000097:blood; D002177:Candidiasis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D002648:Child; D004198:Disease Susceptibility; D019337:Hematologic Neoplasms / Q000150:complications* / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D016867:Immunocompromised Host; D009172:Mycology / Q000379:methods* / Q000639:trends; D009181:Mycoses / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications; D012306:Risk
D000935:Antifungal Agents; D000970:Antineoplastic Agents; D015415:Biomarkers